Literature DB >> 324620

Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.

H T Mouridsen, T Palshof, M Brahm, I Rahbek.   

Abstract

Fifty-one postmenopausal patients with advanced breast cancer were randomized to receive either cyclophosphamide given continuously or cyclophosphamide given continuously with methotrexate, 5-fluorouracil, vincristine, and prednisone given intermittently. The results with the multiple-drug therapy were significantly better than with the single-drug therapy, both with regard to percentage (63% versus 25%) and median duration (400 versus 210 days) of objective response. Toxicity was moderately increased with the combination as compared to the single-drug treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324620

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

Review 1.  Systemic therapy of advanced breast cancer.

Authors:  H T Mouridsen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

2.  Mitoxantrone as a first-line treatment of advanced breast cancer.

Authors:  K Landys; S Borgstrom; T Andersson; H Noppa
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 3.  Why does cytotoxic chemotherapy cure only some cancers?

Authors:  Philip Savage; Justin Stebbing; Mark Bower; Tim Crook
Journal:  Nat Clin Pract Oncol       Date:  2008-11-04

4.  A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer.

Authors:  J Carmo-Pereira; F O Costa; E Henriques; V Carvalho
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Postmenopausal breast cancer. Drug therapy in the 1990s.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

Review 6.  Single agent versus combination chemotherapy for metastatic breast cancer.

Authors:  Sue Carrick; Sharon Parker; Charlene E Thornton; Davina Ghersi; John Simes; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

7.  Photodynamic effect of Zirconium phosphate biocompatible nano-bilayers containing methylene blue on cancer and normal cells.

Authors:  Reza Hosseinzadeh; Khatereh Khorsandi
Journal:  Sci Rep       Date:  2019-10-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.